新辅助化疗治疗晚期卵巢癌的临床效果分析

Analysis of the Clinical Effect of Neoadjuvant Chemotherapy in the Treatment of Advanced Ovarian Cancer

目的探讨对晚期卵巢癌患者实施新辅助化疗后获得临床效果。方法随机选取2018年1月—2020年12月收治的200例晚期卵巢癌(Ⅲ~Ⅳ期)患者进行治疗研究;随机分为参照组(对患者合理实施手术治疗)和研究组(在参照组基础上,添加新辅助化疗1~3周期),每组100例;比较两组患者疾病总缓解率、术中失血量、手术时间、癌抗原125(CA125)水平以及术中腹水量。结果研究组疾病总缓解率(96.00%)高于参照组(82.00%),差异有统计学意义(χ^(2)=10.010,P<0.05);研究组术中失血量(485.25±12.35)mL、手术时间(2.13±0.57)h、CA125水平(505.25±122.35)U/mL以及术中腹水量(242.53±22.35)mL均优于参照组,差异有统计学意义(t=130.478、21.891、26.704、141.279,P<0.05)。结论对于晚期卵巢癌进行新辅助化疗后,患者疾病总缓解率、术中失血量、手术时间、CA125水平以及术中腹水量,均获得显著改善,可使晚期卵巢癌患者临床效果以及预后水平显著提升,充分证明新辅助化疗方式运用于晚期卵巢癌疾病治疗中临床价值。

Objective To explore the clinical effects of neoadjuvant chemotherapy for patients with advanced ovarian cancer.Methods Randomly selected 200 patients with advanced ovarian cancer(stageⅢ-Ⅳ)who were admitted from January 2018 to December 2020 for treatment research;randomly divideded them into reference group(appropriate surgical treatment for patients in reference group)and study group(On the basis,add neoadjuvant chemotherapy 1-3 cycles),100 cases in each group;compared the total disease remission rate,intraoperative blood loss,operation time,cancer antigen 125(CA125)level and intraoperative ascites volume between the two groups.Results The total disease remission rate of the study group(96.00%)was higher than that of the reference group(82.00%),and the difference was statistically significant(χ^(2)=10.010,P<0.05);the blood loss in the study group was(485.25±12.35)mL,operation time(2.13±0.57)h,CA125 level(505.25±122.35)U/mL and intraoperative ascites volume(242.53±22.35)mL were all better than the reference group,the difference was statistically significant(t=130.478,21.891,26.704,141.279,P<0.05).Conclusion After neoadjuvant chemotherapy for advanced ovarian cancer,the patient's total disease remission rate,intraoperative blood loss,operation time,CA125 level and intraoperative ascites were all significantly improved.It can significantly improve the clinical effect and prognosis of patients with advanced ovarian cancer,and fully prove the clinical value of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer.